HK-2 Hücrelerinde Anti-HLA Antikorlarının mRNA ve miRNA Ekspresyonu Üzerindeki Etkisi

Aslı ELDEM[1], Tülay Kılıçaslan AYNA[1], Melek PEHLİVAN[2], Mustafa SOYÖZ[1], Cem TUĞMEN[3], İbrahim PİRİM[1]

[1]İzmir Katip Çelebi Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji ve Genetik A.D., İzmir, Türkiye
[2]İzmir Katip Çelebi Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, İzmir, Türkiye
[3]İzmir Bakırçay Üniversitesi, Cerrahi Tıp Bilimleri, Genel Cerrahi A.D., İzmir, Türkiye

18-21 Nisan 2024 / Antalya

GİRİŞ



Böbrek Nakli Başarısını Etkileyen Temel Faktörler

Alıcı-donör HLA uyumluluğu
ABO kan grubu
Donöre özgü antikorlar

mRNA:
TGF-β
C1qA
C1qB
C1qC
TNF-α
Kaspaz-3

miRNA:
let-7c-5p
miR-21
miR-28-3p
miR-29b-3p
miR-125a-5p
miR-142-5p
miR-145
miR-155
miR-217
miR-520e
miR-885

YÖNTEM

HK-2 hücresi

HLA-A	HLA-B	HLA-C	HLA-DRB1	HLA-DQB1
02:01	13:02	02:02	01:01	05:01
30:01	44:05	06:02	16:01	05:02

Hasta X PRA: anti-HLA A2

Report Parameters

Method Type: Standard Calculation

Positive MFI:	CON 1 MFI:	CON 2 MFI:	CON 3 MFI:	Cal CON MFI:	Adjust Value Cutoff Value:	Assignment Cutoff:
21967	126	243	96	295	0.0	2

Tail Type:	Tail Sort By:	R-Value Cutoff:	% Positive Cutoff:
MANUAL	R-Value	0.00	50

Tail Antigens

Specificity	TP(++)	FP(+-)	FN(-+)	TN(--)	N	Chi²	R-Value	% Positive	Strength
A2	7	39	0	4	50	0.71	0.12	100	15525
A68	6	33	0	4	43	0.72	0.13	100	19297
B35	5	28	0	4	37	0.70	0.14	100	11557
A69	1	27	0	4	32	0.15	0.07	100	14012
A33	5	22	0	4	31	0.88	0.17	100	8707
A29	1	21	0	4	26	0.19	0.09	100	16331
B72	1	20	0	4	25	0.20	0.09	100	4218
B58	3	17	0	4	24	0.69	0.17	100	8249
B45	2	15	0	4	21	0.52	0.16	100	8926
A24	5	10	0	4	19	1.81	0.31	100	8106
						2.24	0.40	100	6887

YÖNTEM


HK-2 hücreleri
DSA (-) serum
DSA (+) serum
HK-2
DSA(-)
DSA(+)
HK-2
A
B
C
A2
HK-2 hücreleri
DSA (-) serum
DSA (+) serum
İnkübasyon
Kompleman
HK-2
DSA(-)
DSA(+)
HK-2
A
B
C

BULGULAR

Review > Int Urol Nephrol. 2022 Mar;54(3):575-588. doi: 10.1007/s11255-021-02922-7. Epub 2021 Jul 6.

miRNA biomarkers in renal disease

Beata Franczyk [1], Anna Gluba-Brzózka [2], Robert Olszewski [3 4], Magdalena Parolczyk [1], Magdalena Rysz-Górzyńska [5], Jacek Rysz [1]

Affiliations + expand

PMID: 34228259 PMCID: PMC8831254 DOI: 10.1007/s11255-021-02922-7





(Grafik Log 10 olarak gösterilmiştir.) *p<0,05

BULGULAR





CDC C (-): Komplemansız CDC (Grafik Log 10 olarak gösterilmiştir.) *p<0,05

BULGULAR





CDC C (+): Komplemanlı CDC (Grafik Log 10 olarak gösterilmiştir.) *p<0,05

BULGULAR



	Artan	Azalan
C(-)	TGF-β, C1qA, **C1qB,** C1qC, kaspaz3	**TNF-α**
C(+)	TGF-β, C1qA, C1qC, **TNF-α** kaspaz3	**C1qB**

	Artan	Azalan
C(-)	Let-7c-5p, **miR-21, miR-28-3p, miR-29b-3p, miR-145, miR-217,** miR-520e	**miR-125a-5p**, **miR-142-5p, miR-155**, miR-885
C(+)	Let-7c-5p, miR-28-3p, **miR-125a-5p**, **miR-142-5p, miR-155**, miR-520e	**miR-21, miR-29b-3p**, **miR-145, miR-217,** miR-885

C-:Komplemansız; C+: Komplemanlı

BULGULAR

Hypoxia-induced microRNA-155 promotes fibrosis in proximal tubule cells

Authors: Shenping Xie, Huaizhou Chen, Fei Li, Shu Wang, Junjun Guo





CDC C (+): Komplemanlı CDC (Grafik Log 10 olarak gösterilmiştir.) *p<0,05

SONUÇ VE ÖNERİLER



Biyobelirteç

Kompleman Proteini ???

In vitro AAR modeli

KAYNAKLAR

- Heinemann, F. M., Jindra, P. T., Bockmeyer, C. L., Zeuschner, P., Wittig, J., Höflich, H., ... & Becker, J. U. Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo. Scientific reports, 2017; 7(1), 14554. DOI:10.1038/s41598-017-14674-5

- Thurman, J. M., Panzer, S. E., & Le Quintrec, M. The role of complement in antibody mediated transplant rejection. *Molecular immunology*, 2019; *112*, 240-246. doi.org/10.1016/j.molimm.2019.06.002

- Boštjančič, E., Večerić-Haler, Ž., & Kojc, N. The Role of Immune-Related miRNAs in the Pathology of Kidney Transplantation. *Biomolecules*, 2021; *11*(8), 1198. doi.org/10.3390/biom11081198

Dinlediğiniz için Teşekkür Ederim